{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:03:02Z","timestamp":1789970582243,"version":"4.0.1"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oesophageal adenocarcinoma (OAC) is a highly mutated cancer with poor survival. While outcomes are improving, long-term survival remains elusive for the majority of patients. Immunotherapy in combination with chemotherapy has shown benefit but is effective in only a subset of patients, highlighting the lack of reliable genomic biomarkers for response and survival. Effective anti-tumour immune responses, including those targeting neoantigens, are critical for durable outcomes. However, their role in long-term OAC survivors remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Whole-genome, whole-exome, and RNA sequencing data was used to identify (expressed) putative neoantigens from two independent OAC cohorts. We combined data from the Extended-DOCTOR (ExtDOC; n=149) and the TCGA ESCA (n=88) cohort to profile the neoantigen landscape in OAC. 95 patients of the ExtDOC cohort were enrolled in the DOCTOR trial, sponsored by the GI Cancer Trials. Selected putative neoantigens from 14 patients underwent\n                      <jats:italic>in vitro<\/jats:italic>\n                      validation using HLA-matched healthy donor and patient-derived PBMCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified a median of 23 neoantigens per tumour sample which were mostly 9- and 10-mers predicted to bind to HLA-A molecules. Low stromal and immune exclusion scores as well as high-quality neoantigens with high expressed differential agretopicity index (DAI), a measure of immunogenicity, were linked to good survival outcomes. We observed intra-tumour heterogeneity and found immunogenic putative neoantigens for 12\/14 patients. The tumour environment (TME) revealed three immune clusters which were associated with patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We showed that OAC is characterised by a complex and largely immunosuppressive TME. In our cohort, patients with an immune-enriched TME had more favourable outcomes, including higher response rates, lower disease recurrence and longer survival. This might be linked to the presence of high-quality neoantigens. Together, these findings provide a rationale for the development of tailored, immune-informed treatment strategies in OAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1926114","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:36:22Z","timestamp":1789968982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The neoantigen and associated tumour microenvironment in long-term survivors with oesophageal adenocarcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"James M.","family":"Lonie","sequence":"first","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"Department of Upper Gastrointestinal Surgery, Princess Alexandra Hospital","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Brosda","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswar","family":"Addala","sequence":"additional","affiliation":[{"name":"Medical Genomics, QIMR Berghofer Medical Research Institute","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijun","family":"Zeng","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"Peter MacCallum Cancer Centre","place":["Melbourne, VIC, Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"Immunopathology Group, Mater Research Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa F.","family":"Bonazzi","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren G.","family":"Aoude","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros T.","family":"Koufariotis","sequence":"additional","affiliation":[{"name":"Medical Genomics, QIMR Berghofer Medical Research Institute","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Patel","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katina D.","family":"Hulme","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence J.","family":"Belle","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wood","sequence":"additional","affiliation":[{"name":"Medical Genomics, QIMR Berghofer Medical Research Institute","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medical Genomics, QIMR Berghofer Medical Research Institute","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Waddell","sequence":"additional","affiliation":[{"name":"Medical Genomics, QIMR Berghofer Medical Research Institute","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Dolcetti","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"Peter MacCallum Cancer Centre","place":["Melbourne, VIC, Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne","place":["Melbourne, VIC, Australia"]},{"name":"Department of Microbiology and Immunology, The University of Melbourne","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Barbour","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"Department of Upper Gastrointestinal Surgery, Princess Alexandra Hospital","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102219","article-title":"Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches","volume":"98","author":"Lonie","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1220129","article-title":"The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank","volume":"14","author":"Lonie","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1038\/s41467-023-38891-x","article-title":"Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy","volume":"14","author":"Naeini","year":"2023","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13073-024-01362-z","article-title":"Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy","volume":"16","author":"Brosda","year":"2024","journal-title":"Genome Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141135","article-title":"Does the immune system see tumors as foreign or self","volume":"21","author":"Pardoll","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Luksza","year":"2022","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13578","article-title":"Identification of neoantigens in oesophageal adenocarcinoma","volume":"168","author":"Nicholas","year":"2023","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3659","article-title":"Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance","volume":"48","author":"Secrier","year":"2016","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.019","article-title":"Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial","volume":"31","author":"Barbour","year":"2020","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000004638","article-title":"Survival after trimodality therapy in patients with locally advanced esophagogastric adenocarcinoma: Does only a complete pathologic response matter","volume":"276","author":"Sihag","year":"2022","journal-title":"Ann Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinf (Oxford England)"},{"key":"B24","unstructured":"Picard Markduplicates"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074380","article-title":"Somatic point mutation calling in low cellularity tumors","volume":"8","author":"Kassahn","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.17","article-title":"ascatNgs: Identifying somatically acquired copy-number alterations from whole-genome sequencing data","volume":"56","author":"Raine","year":"2016","journal-title":"Curr Protoc Bioinf"},{"key":"B29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","article-title":"Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data","volume":"26","author":"Favero","year":"2015","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"24","author":"Martin","year":"2011","journal-title":"EMBnetjournal"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinf (Oxford England)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinf (Oxford England)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinf (Oxford England)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0264-5","article-title":"pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens","volume":"8","author":"Hundal","year":"2016","journal-title":"Genome Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141308","article-title":"Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity","volume":"211","author":"Duan","year":"2014","journal-title":"J Exp Med"},{"key":"B44","unstructured":"Qbasepileup"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx687","article-title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","volume":"29","author":"Ghorani","year":"2018","journal-title":"Ann Oncol"},{"key":"B46","volume-title":"R: A Language and Environment for Statistical Computing","year":"2017"},{"key":"B47","article-title":"A package for survival analysis in R","author":"Therneau","year":"2022"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.32614\/cran.package.survminer","article-title":"survminer: drawing survival curves using 'ggplot2'","author":"Kassambara","year":"2018"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1201\/9781003597162-33","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","year":"2017","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/gr.214296.116","article-title":"A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy","volume":"27","author":"Noorani","year":"2017","journal-title":"Genome Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1093\/dote\/doaa087.122","article-title":"Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma","volume":"13","author":"Izadi","year":"2021","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1038\/s41598-018-30724-y","article-title":"Pan-cancer analysis of neoepitopes","volume":"8","author":"Teku","year":"2018","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-1494","article-title":"Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discov"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0412","article-title":"Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy","volume":"5","author":"Murugaesu","year":"2015","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11111","article-title":"Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy","volume":"7","author":"Findlay","year":"2016","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3357","article-title":"Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma","volume":"47","author":"Ross-Innes","year":"2015","journal-title":"Nat Genet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100541","article-title":"Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts","volume":"3","author":"Sharpe","year":"2022","journal-title":"Cell Rep Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820459116","article-title":"Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma","volume":"116","author":"Ebbing","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3492","article-title":"Tumor-induced stromal reprogramming drives lymph node transformation","volume":"17","author":"Riedel","year":"2016","journal-title":"Nat Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/path.4467","article-title":"Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma","volume":"235","author":"Underwood","year":"2015","journal-title":"J Pathol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"200","DOI":"10.21203\/rs.3.rs-1890491\/v1","article-title":"The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy","volume":"21","author":"Croft","year":"2022","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41698-025-01223-x","article-title":"Quantitative profiling of intratumor immune heterogeneity identifies loss of immune diversity as a hallmark of cancer progression","volume":"10","author":"Lu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012491","article-title":"Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid\/Siglec axis","volume":"13","author":"O'Neill","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.aacriaslc18-ia23","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4443","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"van den Ende","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.3390\/cancers13205173","article-title":"Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma","volume":"13","author":"Lopez-Carrasco","year":"2021","journal-title":"Cancers"},{"key":"B77","doi-asserted-by":"publisher","first-page":"101357","DOI":"10.1016\/j.xinn.2026.101357","article-title":"Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy","volume":"7","author":"Wang","year":"2026","journal-title":"Innovation"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.05.002","article-title":"Subclonal immune evasion in non-small cell lung cancer","volume":"44","author":"Dijkstra","year":"2026","journal-title":"Cancer Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617654","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.3390\/ijms231710131","article-title":"Sources of cancer neoantigens beyond single-nucleotide variants","volume":"23","author":"Capietto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-061521-101910","article-title":"The effects of clonal heterogeneity on cancer immunosurveillance","volume":"7","author":"Dijkstra","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:36:25Z","timestamp":1789968985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2026.1926114"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1926114","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1926114"}}